Skip to Content

Generex's New Vaccine Technology Could Speed Flu Vaccine Availability

WORCESTER, Mass., Jun 26, 2009 -- Antigen Express Inc., a wholly owned subsidiary of Generex Biotechnology Corporation (Nasdaq:GNBT), has developed new vaccine technology that "could rapidly lead to safe, effective flu vaccines," according to a June 23, 2009 article in the Worcester, Massachusetts Telegram & Gazette.

"It's not a biological process, it's a chemical process," explained Douglas M. Powell, PhD, director of immunobiology at Antigen Express. "It's not futuristic, it's here now."

The article notes that in contrast with traditional vaccines, which require literally cracking millions of hen eggs, Antigen Express uses lab equipment to string together amino acids into peptides that can stimulate the body to produce immune cells in response to specific threats, such as influenza.

"If Antigen Express could develop an H1N1 vaccine, large-scale production could take place rapidly in existing facilities," Dr. Powell said. "The capacity exists now that you could literally make billions of doses of this vaccine."

Earlier this month, Generex announced positive results of a recently completed Phase I trial of its prostate cancer vaccine. The immunotherapeutic peptide AE37 is also being developed by Antigen Express for multiple cancer indications.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Posted: June 2009